MMI Raises $125M Series C+ Led by BioStar Capital for Robotic Microsurgery

MMI Secures $125M Series C+ to Advance Robotic Microsurgery

MMI (Medical Microinstruments) has raised a $125 million Series C+ round led by BioStar Capital, with participation from S3 Ventures and Angelini Ventures. The funding was announced on October 8, 2026.

What MMI Does

MMI develops robotic solutions for microsurgery and super-microsurgery. Its flagship product, the Symani Surgical System, pairs the world's smallest articulated robotic micro-instruments with tremor-reduction and motion-scaling technology. This combination enables surgeons to operate on structures as small as 0.1 mm.

The system addresses indications including trauma and head-and-neck reconstruction, breast cancer surgery, and lymphatic repair.

Company Background

Founded in Italy in 2015, MMI manufactures the Symani Surgical System at its Pisa facility. The company was the first to have a robotic system of its kind approved by the FDA for reconstructive microsurgery in the United States.

The Round at a Glance

• Round type: Series C+
• Amount: $125 million
• Currency: USD
• Date: October 8, 2026
• Lead investor: BioStar Capital
• Additional investors: S3 Ventures, Angelini Ventures

Why This Matters for the Microsurgery Market

Microsurgery and super-microsurgery demand extraordinary precision. Procedures involving vessels, nerves, and lymphatic structures measured in fractions of a millimeter leave little margin for error. MMI's approach combines robotic instrumentation with motion scaling and tremor reduction, directly targeting the physical limits that constrain human surgeons in these procedures.

The FDA approval for reconstructive microsurgery in the US gives MMI a regulatory foothold in the largest medical device market. Manufacturing in Pisa keeps development and production integrated as the company scales.

Acquisition and Strategic Context

The Series C+ structure suggests MMI is extending its runway ahead of a potential commercial inflection point rather than marking an early-stage milestone. For strategic acquirers in surgical robotics, MMI represents a differentiated asset: a company with an FDA-approved robotic platform in a niche where few competitors operate, backed by a syndicate that includes BioStar Capital, S3 Ventures, and Angelini Ventures.

BioStar Capital's lead position signals continued conviction from an investor base focused on medical technology. Angelini Ventures' participation adds an Italian and European industrial perspective, while S3 Ventures brings US venture backing.

What to Watch

• Commercial expansion of the Symani Surgical System in the US following FDA approval
• Adoption across the named indications: trauma and head-and-neck reconstruction, breast cancer surgery, and lymphatic repair
• Manufacturing scale-up at the Pisa facility
• How the $125 million is deployed across clinical, commercial, and R&D functions

MMI sits at the intersection of surgical robotics and microsurgery, two areas where acquisition interest has been persistent. With a fresh $125 million and a syndicate led by BioStar Capital, the company has the capital to pursue its next phase of growth.